Background: Altered intestinal function is prevalent in patients with heart failure (HF), but its
role in adverse outcomes is unclear. Objectives: This study investigated the potential …

Objectives Recent metabolomic, experimental and clinical studies have demonstrated that
trimethylamine‐N‐oxide (TMAO), a microbiota‐dependent metabolite from dietary …

Objective Gut microbiota‐produced trimethylamine N‐oxide (TMAO) is a risk factor for
cardiovascular events. However, conflicting findings regarding the link between plasma …

Aim Accumulating evidence has demonstrated that intestinal microbiota‐dependent
trimethylamine N‐oxide (TMAO) is involved in the pathogenesis of various cardiovascular …

There is an expanding body of research on the bidirectional relationship of the human gut
microbiome and cardiovascular disease, including heart failure (HF). Researchers are …

Abstract Background Trimethylamine-N-oxide (TMAO) has been linked to increased
cardiovascular risk. We aimed to determine the prognostic value of TMAO and its dietary …

An increasing amount of evidence reveals that the gut microbiota is involved in the
pathogenesis and progression of various cardiovascular diseases. In patients with heart …

Aims Association of elevated circulating levels of trimethylamine N‐oxide (TMAO) with
adverse outcomes in patients with heart failure (HF) has been described. However …

Objective Acute heart failure (AHF) is associated with high mortality and morbidity.
Trimethylamine N-oxide (TMAO), a gut-derived metabolite, has reported association with …

BACKGROUND Recent studies show a mechanistic link between intestinal microbial
metabolism of dietary phosphatidylcholine and coronary artery disease pathogenesis …